InBios has a long history of market leadership. Since our founding in 1996, InBios has successfully developed proprietary technologies used to create rapid and ELISA based immunodiagnostic assays for the world’s most devastating infectious diseases. With broad experience in successfully navigating regulatory pathways, we have FDA-cleared ELISA kits for Zika, dengue, and West Nile and rapid test kits for Chagas and leishmaniasis. Most recently, we responded to the coronavirus crisis, receiving FDA EUAs for seven COVID-19 products while continuing to develop other tests to fight this pandemic. InBios also specializes in the development and manufacture of highly specific and well-characterized antibodies and antigens for use in infectious disease research.

Quality is key to our success. With quality of utmost importance, all InBios products are manufactured in the United States under rigorous quality control and performance validation procedures. InBios is GMP compliant, FDA registered, USDA licensed and ISO 13485:2016 certified. Most products are CE Marked according to EC IVD Directive 98/79/EC.

Our services help you with your business. InBios is a total solution company with expertise in all facets of the product pipeline, from discovery to application. From concept to clinic, InBios partners with private companies, federal laboratories and academia to bring our customers the best scientific solutions for their diagnostic needs. While we continue to develop new products to complement our existing product range, we can also assist you with assay development or contract manufacturing services.

InBios - Model NuGen™ ZIKV IgG -Capture ELISA Kit